These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 38542278)

  • 1. Targeting
    Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
    Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
    N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
    Desai J; Alonso G; Kim SH; Cervantes A; Karasic T; Medina L; Shacham-Shmueli E; Cosman R; Falcon A; Gort E; Guren T; Massarelli E; Miller WH; Paz-Ares L; Prenen H; Amatu A; Cremolini C; Kim TW; Moreno V; Ou SI; Passardi A; Sacher A; Santoro A; Stec R; Ulahannan S; Arbour K; Lorusso P; Luo J; Patel MR; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Jun T; Dharia NV; Schutzman JL; ; Han SW
    Nat Med; 2024 Jan; 30(1):271-278. PubMed ID: 38052910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotorasib with panitumumab in chemotherapy-refractory KRAS
    Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
    Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y
    Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
    Kavgaci G; Dizdar O; Yalcin S
    Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
    Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
    Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
    Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.